Prescient Therapeutics Ltd (ASX:PTX) has been invited to present two sessions at the upcoming CAR-TCR Summit in Boston on September 19 to 22, during which the clinical stage oncology company will also unveil CellPryme-A, the enhanced component of its cell therapy platform CellPryme.
The company's senior vice president of Scientific Affairs Dr Rebecca Lim will present on ‘Enhancing Persistence & Efficacy of CAR-T Therapies’ on September 21, as well as introduce CellPryme-A.
Prescient’s vice president of Business Development and Alliances Dr Daniel Shelly will speak on the advantages and capabilities of the OmniCAR technology during the session ‘Simultaneous & Sequential Multi-Antigen Targeting with a Novel Universal Immune Receptor’ on the last day of the conference.
About CellPryme-M
Prescient’s novel, ready-for-the-clinic CellPryme-M is a 24-hour, non-disruptive process during cell manufacturing.
The technology enhances adoptive cell therapy performance by shifting T and NK cells towards a central memory phenotype, improving persistence and increasing the ability to find and penetrate tumours.
Prescient is developing personalised medicine approaches to cancer, including targeted and cellular therapies.
Its OmniCAR programs are focused on next-generation CAR-T therapies for Acute Myeloid Leukemia (AML), Her2+ solid tumours, including breast, ovarian and gastric cancers, as well as glioblastoma multiforme, an aggressive type of cancer occurring in the brain or spinal cord.